Abstract
Hypertriglyceridemia is a polyetiological lipid metabolism disorder, which is characterized by an increased residual risk of atherosclerosis-associated cardiovascular system pathology. This literature review presents current data on aspects of drug therapy for this dyslipidemia, which allows for a more comprehensive approach to the treatment strategies. This analysis is based on modern sources, the materials of which were published from 2010 to 2024 in Russian and English in international scientific online libraries. The article discusses the main drugs groups to consider the phenomenon under consideration: niacin, fibrates, omega-3 polyunsaturated fatty acids. The analysis of research results indicates that the prescription of drugs aimed at reducing triglyceride levels is a promising direction in advanced lipidology. The most promising drugs at the moment are omega-3 polyunsaturated fatty acids, fibric acid agents, and evinacumab. The pharmacological correction features of high triglyceride levels and promising therapeutic directions are highlighted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
